Christer Tannergren, PhD, Principal Scientist in Biopharmaceutics at Oral Product Development, Pharmaceutical Technology & Development, AstraZeneca Gothenburg, Sweden. He received his PhD in Biopharmaceutics at the Department of Pharmacy, Uppsala University, Sweden in 2004. He has held various Biopharmaceutics expert positions and Product Development Lead roles since joining AstraZeneca in 2003. His main areas of research interest include physiologically based biopharmaceutics modelling and regional intestinal absorption/bioavailability as well as development of low solubility and Modified Release drug products. He has co-supervised 3 PhD students and is author of 35 peer-reviewed papers as well as inventor of 1 formulation patent.
Don't miss
- Alessia Favaron successfully defending her PhD on how JAK inhibitor drugs for inflammatory bowel disease (IBD) interact with the human gut microbiome
- Outstanding cum laude! 1st COLOTAN PhD defence by Ines Pârente
- A new COLOTAN publication that explores the potential of human intestinal organoids
- A new COLOTAN published article for the better understanding of the luminal conditions in the proximal colon
- Best lecture (runner-up) award at the SoP Research Day goes to COLOTAN’s Alessia!